Nora Schmit was shortlisted for the MRC Max Perutz Science Writing Award 2019 for the following article on her PhD research on predicting the impact of treatment for hepatitis B infection on preventing liver cancer in The Gambia.
What’s the first thing that comes to your mind when you think of cancer prevention? Maybe you’re thinking of not smoking or maintaining a healthy weight – great strategies to reduce your chance of getting cancer.
But did you know that the hepatitis B vaccine, introduced in the 1980s, has long protected children in many parts of the world from developing one of the most common and deadliest cancers later in life?
Although most people have no symptoms when they first become infected, the hepatitis B virus is the leading cause of liver cancer worldwide. Large-scale efforts to tackle the virus using vaccination have been hugely successful in preventing infections in children. Despite this remarkable achievement, hepatitis B infections are still very common and nearly a million people die from its consequences every year. With around 6% of all people living in Africa currently infected, the death toll there is expected to rise even further.
But while a liver cancer diagnosis is nearly always fatal, treating the infection is possible with the same drugs that work against HIV. So why do so few people receive these drugs, when over half of all liver cancer deaths globally are preventable? (more…)
Dr Malick Gibani unravels the mystery behind the role of typhoid toxin in causing typhoid fever – a disease that affects around 11 million people each year globally.
Salmonella Typhi is a fascinatingly complex bacterium. Whilst there are more than 2000 different (sero)types of Salmonella, there’s something special about Salmonella Typhi that sets it apart from the non-typhoidal Salmonella serovars. It causes different symptoms, the means of spread are different and the host it infects is different – specifically, Salmonella Typhi only causes disease in humans.
Understanding the mechanisms of how bacteria can cause disease is profoundly important for vaccine development. The Vi-antigen that forms the major component of injectable typhoid vaccines seems to have a key role in making the bacteria more virulent (hence the name). Vi-based vaccines have proven to be highly effective tools to prevent typhoid. (more…)
When outbreaks emerge, speeding up vaccine development could be the difference between life and death. In this post, Dr Zoltán Kis provides an insight into how Imperial’s chemical engineers are making speedy vaccines a reality.
The worst Ebola epidemic in history swept across West Africa between 2014 to 2016, claiming 11,300 lives. This major outbreak was closely followed by the 2015-2016 Zika epidemic in Latin America. Preventing future epidemics is more important than ever and developing new vaccines are an essential weapon in fighting disease outbreaks. However, with the average vaccine development lasting 10 years, this is not comparable to the speed and frequency of outbreaks which can cause calamity in a matter of months. (more…)
As the Imperial Network for Vaccine Research launches, Dr Chris Chiu tells us why he’s in pursuit of a collaborative approach for developing new vaccines.
Vaccines have been very much in the public eye for a while now, with strong feelings expressed particularly on the side of those who are suspicious of them. As health and scientific professionals, we often try to provide a carefully balanced view but, in this case, it is vitally important that we remember and highlight the massive amount of good that vaccines have done for human health. Once devastating diseases such as smallpox and polio are now gone or almost gone. Vaccines have truly been one of the great triumphs of modern medicine. (more…)